Market Cap | 7.79B | P/E | 31.10 | EPS this Y | 23.90% | Ern Qtrly Grth | 40.70% |
Income | 312.32M | Forward P/E | 26.35 | EPS next Y | 16.70% | 50D Avg Chg | 11.00% |
Sales | 1.96B | PEG | 2.07 | EPS past 5Y | 31.46% | 200D Avg Chg | 21.00% |
Dividend | N/A | Price/Book | 19.91 | EPS next 5Y | 17.91% | 52W High Chg | -3.00% |
Recommedations | 1.50 | Quick Ratio | 0.72 | Shares Outstanding | 30.98M | 52W Low Chg | 81.00% |
Insider Own | 18.16% | ROA | 13.89% | Shares Float | 25.27M | Beta | 1.40 |
Inst Own | 81.98% | ROE | 61.35% | Shares Shorted/Prior | 0.98M/0.96M | Price | 255.29 |
Gross Margin | 66.44% | Profit Margin | 15.92% | Avg. Volume | 360,153 | Target Price | 446.40 |
Oper. Margin | 20.36% | Earnings Date | Jul 22 | Volume | 163,410 | Change | -0.14% |
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Guggenheim | Buy | Apr 24, 24 |
Baird | Outperform | Apr 24, 24 |
Jefferies | Buy | Apr 23, 24 |
Deutsche Bank | Hold | Mar 18, 24 |
UBS | Buy | Mar 8, 24 |
UBS | Buy | Feb 15, 24 |
Baird | Outperform | Feb 14, 24 |
Baird | Outperform | Jan 17, 24 |
Baird | Outperform | Oct 24, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
BURWIG SUSAN E | Exec. VP, Operations Exec. VP, Operations | Dec 14 | Sell | 303.58 | 12,400 | 3,764,392 | 15,283 | 12/18/23 |
BURWIG SUSAN E | Exec. VP, Operations Exec. VP, Operations | Oct 23 | Option | 32.05 | 7,500 | 240,375 | 27,683 | 10/25/23 |
Troendle August J. | CEO CEO | Sep 20 | Sell | 249.88 | 127,308 | 31,811,723 | 5,914,947 | 09/21/23 |
Medpace Investors, LLC | Director Director | Sep 20 | Sell | 249.88 | 127,308 | 31,811,723 | 5,914,947 | 09/21/23 |
Medpace Investors, LLC | 10% Owner 10% Owner | Sep 22 | Buy | 154.59 | 57,426 | 8,877,485 | 6,483,019 | 09/23/22 |
Troendle August J. | CEO CEO | Sep 22 | Buy | 154.59 | 57,426 | 8,877,485 | 6,483,019 | 09/23/22 |
Troendle August J. | CEO CEO | Sep 20 | Buy | 158.39 | 188,238 | 29,815,017 | 6,425,593 | 09/22/22 |
Medpace Investors, LLC | 10% Owner 10% Owner | Sep 20 | Buy | 158.39 | 188,238 | 29,815,017 | 6,425,593 | 09/22/22 |
Troendle August J. | CEO CEO | Jul 18 | Buy | 145.00 | 8,330 | 1,207,850 | 5,513,639 | 07/20/22 |
Medpace Investors, LLC | 10% Owner 10% Owner | Jul 18 | Buy | 145.00 | 8,330 | 1,207,850 | 5,513,639 | 07/20/22 |
DAVENPORT FRED B JR | Director Director | Feb 17 | Buy | 145.80 | 500 | 72,900 | 2,000 | 02/22/22 |
Troendle August J. | CEO CEO | Dec 28 | Sell | 221.17 | 40,868 | 9,038,776 | 5,536,546 | 12/30/21 |
Medpace Investors, LLC | 10% Owner 10% Owner | Apr 16 | Sell | 182.48 | 52,518 | 9,583,485 | 6,404,684 | 04/16/21 |
EWALD STEPHEN P | General Counsel & Co.. General Counsel & Corp. Secy. | Apr 16 | Option | 28.32 | 5,000 | 141,600 | 17,654 | 04/16/21 |
EWALD STEPHEN P | General Counsel & Co.. General Counsel & Corp. Secy. | Apr 16 | Sell | 182.93 | 5,000 | 914,650 | 13,854 | 04/16/21 |
GEIGER JESSE J | CFO & COO, Lab Opera.. CFO & COO, Lab Operations | Apr 16 | Option | 28.32 | 3,000 | 84,960 | 9,382 | 04/16/21 |
Troendle August J. | President & CEO President & CEO | Apr 16 | Sell | 182.48 | 52,518 | 9,583,485 | 6,404,684 | 04/16/21 |
GEIGER JESSE J | CFO & COO, Lab Opera.. CFO & COO, Lab Operations | Feb 11 | Option | 23 | 4,000 | 92,000 | 10,382 | 02/11/21 |
GEIGER JESSE J | CFO & COO, Lab Opera.. CFO & COO, Lab Operations | Feb 11 | Sell | 160 | 4,000 | 640,000 | 6,382 | 02/11/21 |
Medpace Investors, LLC | 10% Owner 10% Owner | Jan 08 | Sell | 140.06 | 185,219 | 25,941,773 | 6,483,868 | 01/08/21 |
Medpace Investors, LLC | 10% Owner 10% Owner | Jan 07 | Option | 16.03 | 185,347 | 2,971,112 | 6,669,087 | 01/07/21 |
Troendle August J. | President & CEO President & CEO | Dec 29 | Option | 54.74 | 40,000 | 2,189,600 | 706,643 | 12/29/20 |
Troendle August J. | President & CEO President & CEO | Dec 29 | Sell | 140.04 | 8,750 | 1,225,350 | 6,513,797 | 12/29/20 |
Medpace Investors, LLC | 10% Owner 10% Owner | Dec 29 | Sell | 140.04 | 8,750 | 1,225,350 | 6,513,797 | 12/29/20 |
EWALD STEPHEN P | General Counsel & Co.. General Counsel & Corp. Secy. | Dec 14 | Option | 90.65 | 10,000 | 906,500 | 23,854 | 12/14/20 |
EWALD STEPHEN P | General Counsel & Co.. General Counsel & Corp. Secy. | Dec 14 | Sell | 140.07 | 10,000 | 1,400,700 | 13,854 | 12/14/20 |